Retrospective Comparative Analysis of Spectra Optia® MNC and Cmnc Apheresis Collection Protocols

Paul Shaughnessy(CHRISTUS Transplant Institute), Peter A. McSweeney(Mesoblast (United States)), Mary Kay Nalty(Presbyterian St. Luke's Medical Center), Betsy Blunk(Sarah Cannon), Carijo West(Presbyterian St. Luke's Medical Center), Gayla Nagy(Methodist Hospital), Dorothy Jo Stevens(Methodist Hospital), Joseph Roig(Terumo (United States))
Transplantation and Cellular Therapy
February 22, 2017
10.1016/j.bbmt.2016.12.510
Cited by 1

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645